Ensysce Biosciences Inc (ENSC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has a cash flow conversion efficiency ratio of -0.529x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.53 Million) by net assets ($2.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ensysce Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Ensysce Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Ensysce Biosciences Inc for a breakdown of total debt and financial obligations.
Ensysce Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ensysce Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Randgold Exploration
JSE:RNG
|
0.000x |
|
AquaBounty Technologies Inc
NASDAQ:AQB
|
-134.911x |
|
Mare Nostrum
PA:ALMAR
|
-0.054x |
|
IPB Petroleum Ltd
AU:IPB
|
0.000x |
|
49 North Resources Inc
V:FNR
|
0.003x |
|
Emetals Ltd
AU:EMT
|
-0.055x |
|
NR 21 S.A.
PA:NR21
|
-0.008x |
|
Fintec Global Bhd
KLSE:0150
|
0.001x |
Annual Cash Flow Conversion Efficiency for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Ensysce Biosciences Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Ensysce Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.88 Trillion | $-7.81 Trillion | -2.706x | +100.00% |
| 2024-12-31 | $3.38 Million | $-7.50 Trillion | -2219773.789x | -13410747.77% |
| 2023-12-31 | $-651.27K | $-10.78 Million | 16.552x | +272.89% |
| 2022-12-31 | $-4.03 Million | $-17.89 Million | 4.439x | +339.37% |
| 2021-12-31 | $-8.16 Million | $-8.24 Million | 1.010x | +439.31% |
| 2020-12-31 | $-6.66 Million | $-1.25 Million | 0.187x | +217.21% |
| 2019-12-31 | $186.17 Million | $10.99 Million | 0.059x | +1041.43% |
| 2018-12-31 | $197.39 Million | $-1.24 Million | -0.006x | -386.42% |
| 2017-12-31 | $195.27 Million | $-251.83K | -0.001x | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more